URGN
URGN
NASDAQ · Biotechnology

Urogen Pharma Ltd

$24.75
-0.98 (-3.81%)
As of Nov 7, 1:54 AM ET ·
Financial Highlights (FY 2026)
Revenue
117.09M
Net Income
-163,708,752
Gross Margin
88.7%
Profit Margin
-139.8%
Rev Growth
+19.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 88.7% 88.7% 31.9% 31.9%
Operating Margin -113.7% -102.4% 7.4% 7.0%
Profit Margin -139.8% -132.8% 5.1% 6.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 117.09M 98.00M 574.93M 620.56M
Gross Profit 103.81M 86.89M 183.53M 198.10M
Operating Income -133,168,400 -100,310,980 42.60M 43.31M
Net Income -163,708,752 -123,315,933 29.33M 36.90M
Gross Margin 88.7% 88.7% 31.9% 31.9%
Operating Margin -113.7% -102.4% 7.4% 7.0%
Profit Margin -139.8% -132.8% 5.1% 6.0%
Rev Growth +19.5% +19.5% -7.8% +0.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 316.20M 293.87M
Total Equity — — 463.52M 437.50M
D/E Ratio — — 0.68 0.67
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -132,846,258 -105,627,674 65.79M 68.95M
Free Cash Flow — — 30.48M 44.33M